Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.42 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604524 | 0.90 | PDE4D (0.47) | PDE4BPDE4AROCK2PDE4DPDE4C | |
| SCHEMBL3601367 | 0.90 | NR3C2 (0.42) | PDE4BPDE4APDE4DDRD4PDE4C | |
| SCHEMBL3611676 | 0.90 | PDE4D (0.45) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3604967 | 0.88 | PDE4B (0.41) | PDE4BPDE4APDE4DDRD4PDE4C | |
| SCHEMBL3612474 | 0.87 | PDE4B (0.43) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3611903 | 0.87 | CES2 (0.41) | CES2PDE4BPDE4AROCK2KMT2A | |
| SCHEMBL3599191 | 0.86 | MAPK1 (0.44) | PDE4BPDE4AKMT2APDE4DDRD4 | |
| SCHEMBL3593366 | 0.86 | PDE4B (0.42) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3612777 | 0.85 | PDE4D (0.45) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL3613146 | 0.85 | PDE4B (0.44) | PDE4BPDE4APDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | claimed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | CES2 3562/4885PDE4B 2673/4885PDE4A 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.